Skip to main content
. 2014 Mar 12;1(2):167–179. doi: 10.18632/oncoscience.21

Figure 1. Morphoproteomic analysis of mTOR expression:

Figure 1

First figure (patient 8) shows activation of mTOR pathway in all tumor cells as evidenced by phosphorylation of mTOR at serine 2448, at an intensity of 1-2+, occasionally nuclear, but mostly plasmalemmal and cytoplasmic. Second figure (patient 10) shows activation of the mTOR pathway in a minor component of the tumor cells with both nuclear and cytoplasmic-plasmalemmal expression of pMTOR (Ser 2448). This indicates both mTORC2 and mTORC1 activation, but again only in a minor component of the tumor